human growth hormone raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-20 and is reviewed periodically as new material appears.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
At least three isotopes of iodine are important. 129I, 131I (radioiodine) and 132I. Open air nuclear testing and the Chernobyl disaster both released iodine-131. The short-lived isotopes of iodine are particularly harmful because the thyroid collects and concentrates iodide – radioactive as well as stable. Absorption of radioiodine can lead to acute, chronic, and delayed effects. Acute effects from high doses include thyroiditis, while chronic and delayed effects include hypothyroidism, thyroid nodules, and thyroid cancer. It has been shown that the active iodine released from Chernobyl and Mayak has resulted in an increase in the incidence of thyroid cancer in the former Soviet Union. One measure which protects against the risk from radio-iodine is taking a dose of potassium iodide (KI) before exposure to radioiodine. The non-radioactive iodide "saturates" the thyroid, causing less of the radioiodine to be stored in the body. Administering potassium iodide reduces the effects of radio-iodine by 99% and is a prudent, inexpensive supplement to fallout shelters. A low-cost alternative to commercially available iodine pills is a saturated solution of potassium iodide. Long-term storage of KI is normally in the form of reagent-grade crystals. The administration of known goitrogen substances can also be used as a prophylaxis in reducing the bio-uptake of iodine, (whether it be the nutritional non-radioactive iodine-127 or radioactive iodine, radioiodine - most commonly iodine-131, as the body cannot discern between different iodine isotopes).
1 On 28 July 1998, a reshuffle took place following Eric Charlton's departure from Parliament, with Agricultural MLC Murray Criddle assuming his Transport portfolio. Graham Kierath lost his Labour Relations portfolio to Cheryl Edwardes, whilst Kevin Prince and John Day traded portfolios.
Coicenals are a class of naturally occurring diterpenes extracted from the pathogenic fungus Bipolaris coicis. The four derivatives are named coicenal A-D. These molecules have an underlying bridged-ring structure with an acetaldehyde group. Biosynthetic pathways have been determined for these molecules, but total syntheses have not yet been published.
Sources: en.wikipedia.org
Charles Miller Metzner (1931), judge on the United States District Court for the Southern District of New York and the Temporary Emergency Court of Appeals Lawrence E. Walsh (1932), independent counsel in the Iran-Contra affair; 4th United States Deputy Attorney General William Golub (1934), lawyer and advisor to Governor Nelson Rockefeller Harold Leventhal (1934), judge on the United States Court of Appeals for the District of Columbia Circuit John Slate (1935), lawyer and name partner of Skadden Arps Slate Meagher & Flom Daniel Mortimer Friedman (1937), judge of the United States Court of Appeals for the Federal Circuit, last chief judge of the United States Court of Claims, and acting solicitor general of the United States Wilfred Feinberg (1940), judge of the United States Court of Appeals for the Second Circuit Hugh H. Bownes (1941), judge of the United States Court of Appeals for the First Circuit Richard Kuh (1941), New York County district attorney and prosecutor of Lenny Bruce for obscenity Leonard I. Garth (1942), senior judge on the United States Court of Appeals for the Third Circuit Charles L. Brieant (1944), judge of the United States District Court for the Southern District of New York Jack Greenberg (1945), civil rights lawyer who argued the Brown v. Board of Education case before the United States Supreme Court Roy Cohn (1946), attorney and counsel to Sen. Joseph McCarthy Arthur Lazarus Jr. (1947), American Indian rights lawyer, argued United States v.
== Silver Book == The Silver Book, is formally titled Compendium of Terminology and Nomenclature of Properties in Clinical Laboratory Sciences. The original Silver Book was a publication of the IUPAC, but the second edition was published by the Royal Society of Chemistry.
== Dependence and withdrawal == Nonbenzodiazepines are as addictive as benzodiazepines. Nonbenzodiazepines should not be discontinued abruptly if taken for more than a few weeks due to the risk of rebound withdrawal effects and acute withdrawal reactions, which may resemble those seen during benzodiazepine withdrawal. Treatment usually entails gradually reducing the dosage over a period of weeks or several months depending on the individual, dosage, and length of time the drug has been taken. If this approach fails, a crossover to a benzodiazepine equivalent dose of a long-acting benzodiazepine (such as chlordiazepoxide or more preferably diazepam) can be tried followed by a gradual reduction in dosage. In extreme cases and, in particular, where severe addiction and/or abuse is manifested, an inpatient detoxification may be required.<
== Immobilization == See Immobilized enzyme for more information. There are several reasons for immobilizing an enzyme. In addition to more convenient handling of the enzyme, it provides for its facile separation from the product, thereby minimizing or eliminating protein contamination of the product. Immobilization also facilitates the efficient recovery and re-use of costly enzymes, in many applications a conditio sine qua non for economic viability, and enables their use in continuous, fixed-bed operation. A further benefit is often enhanced stability, under both storage and operational conditions, e.g. towards denaturation by heat or organic solvents or by autolysis. Enzymes are rather delicate molecules that can easily lose their unique three-dimensional structure, essential for their activity, by denaturation (unfolding). Improved enzyme performance via enhanced stability, over a broad pH and temperature range as well as tolerance towards organic solvents, coupled with repeated re-use is reflected in higher catalyst productivities (kg product/kg enzyme) which, in turn, determine the enzyme costs per kg product. Basically, three traditional methods of enzyme immobilization can be distinguished: binding to a support(carrier), entrapment (encapsulation) and cross-linking. Support binding can be physical, ionic, or covalent in nature. However, physical bonding is generally too weak to keep the enzyme fixed to the carrier under industrial conditions of high reactant and product concentrations and high ionic strength.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.